814918-95-1

Usage

Uses

Used in Scientific Research:
5-bromo-4-chlorothieno[2,3-d]pyrimidine is used as a research compound for its unique chemical properties, which make it suitable for various applications in the fields of biochemistry and medicine. Its specific structure allows for potential interactions with biological molecules, making it a valuable tool for studying molecular mechanisms and developing new therapeutic strategies.
Used in Biochemistry:
In the field of biochemistry, 5-bromo-4-chlorothieno[2,3-d]pyrimidine is used as a molecular probe to investigate the interactions between small molecules and biomolecules. Its heterocyclic structure enables it to form specific complexes with proteins, nucleic acids, or other cellular components, providing insights into molecular recognition and binding processes.
Used in Medicinal Chemistry:
5-bromo-4-chlorothieno[2,3-d]pyrimidine is employed as a lead compound in the development of new drugs. Its unique chemical properties and potential to interact with biological targets make it a promising candidate for the design of novel therapeutic agents. Researchers can modify its structure to optimize its pharmacological properties, such as potency, selectivity, and bioavailability, for the treatment of various diseases.
Used in Chemical Synthesis:
5-bromo-4-chlorothieno[2,3-d]pyrimidine serves as a key intermediate in the synthesis of more complex molecules. Its heterocyclic structure can be further functionalized or modified to produce a wide range of chemical products, including pharmaceuticals, agrochemicals, and other specialty chemicals. This versatility makes it an important building block in the field of organic synthesis.
Used in Environmental Research:
Although detailed information on the toxicity, health effects, and environmental impact of 5-bromo-4-chlorothieno[2,3-d]pyrimidine is not readily available, it may be used in environmental research to study the fate and behavior of similar compounds in the environment. Understanding how these chemicals interact with the environment and their potential effects on ecosystems can inform strategies for pollution control and environmental protection.

InChI:InChI=1/C6H2BrClN2S/c7-3-1-11-6-4(3)5(8)9-2-10-6/h1-2H

Upstream product

• 14080-50-3 thieno[2,3-d]pyrimidin-4(1H)-one 
• 56844-40-7 6-bromothieno[2,3-d]pyrimidin-4(3H)-one 
• 14080-50-3 thieno[2,3-d]pyrimidin-4(3H)one 
• 1239460-82-2 5,6-dibromothieno[2,3-d]pyrimidin-4(3H)-one 
• 4651-82-5 2-amino-3-cyanothiophene 
• 56844-12-3 6-bromo-4-chlorothieno[2,3-d]pyrimidine 

Downstream Products

• 885229-27-6 4-chloro-5-iodo-thieno[2,3-d]pyrimidine 
• 885229-24-3 5-Bromo-N-[1-(4-methoxyphenyl)ethyl]thieno[2,3-d]pyrimidin-4-amine 
• 1239460-84-4 5-bromo-4-hydrazinylthieno[2,3-d]pyrimidine 
• 1370338-71-8 4-chloro-5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidine 
• 1370338-31-0 2-methyl-5-(5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidin-4-ylthio)-1,3,4-oxadiazole 
• 1222765-97-0 4-((1-methyl-1H-tetrazol-5-yl)thio)-5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidine 
• 1571111-36-8 6-(4-aminothieno[2,3-d]pyrimidin-5-yl)-N-phenyl-1-naphthalenecarboxamide 
• 1388892-85-0 tert-butyl {(1r,4r)-4-[(5-bromothieno[2,3-d]pyrimidin-4-yl)oxy]cyclohexyl}(methyl)carbamate 
• 1388892-49-6 4-N-[5-(1-benzofuran-2-yl)thieno[2,3-d]pyrimidin-4-yl]-1-N,1-N-dimethylcyclohexane-1,4-diamine 
• 1388892-51-0 4-N-[5-bromothieno[2,3-d]pyrimidin-4-yl]-1-N,1-N-dimethylcyclohexane-1,4-diamine 
• 1388892-88-3 tert-butyl ((1r,4r)-4-{[5-(benzofuran-2-yl)thieno[2,3-d]pyrimidin-4-yl]oxy}cyclohexyl)(methyl)carbamate 
• 1388892-83-8 4-{[5-(1-benzofuran-2-yl)thieno[2,3-d]pyrimidin-4-yl]oxy}-N,N-dimethylcyclohexan-1-amine 
• 1337531-56-2 5-{1-[(3-methylphenyl)acetyl]-2,3-dihydro-1H-indol-5-yl}thieno[2,3-d]pyrimidin-4-amine 
• 1337532-92-9 5-bromo-thieno[2,3-d]pyrimidin-4-ylamine 

Relevant academic research and scientific papers

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS

The invention is directed to substituted pyrrolidinone derivatives. Specifically, the invention is directed to compounds according to Formula X: wherein R41, R42, R43, R44, R45, R46, and R47 are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt- Jakob Disease, and related prion diseases, amyotrophic lateral sclerosis, myocardial infarction, neurodegeneration, cardiovascular disease, atherosclerosis, ocular diseases, and arrhythmias, more specifically cancers of the breast, colon, pancreas and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING OR PREVENTING NEURODEGENERATIVE DISEASES OR DISORDERS

Disclosed are compounds of the formula (I): wherein R1, R2, X, Y, and Z as described herein, or pharmaceutically acceptable salts thereof, for use in treating or preventing neurodegenerative diseases and disorders such as Huntington'

Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration

The SAR of a series of brain penetrant, trisubstituted thiophene based JNK inhibitors with improved pharmacokinetic properties is described. These compounds were designed based on information derived from metabolite identification studies which led to compounds such as 42 with lower clearance, greater brain exposure and longer half life compared to earlier analogs.

INHIBITORS OF JUN N-TERMINAL KINASE

The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

Thieno-pyrimidine compounds having fungicidal activity

The present invention relates to thieno[2,3-d]-pyrimidine compounds having fungicidal activity.

THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS

The present invention provides thienopyrimidine compounds which are potasium channels inhibitors. Pharmaceutical compositions comprising the compounds and their use in the treatment of arrhythmia are also provided.